CureMatch Hires Associate Vice President of Clinical Operations

SAN DIEGO, July 24, 2019 /PRNewswire/ — CureMatch is pleased to announce the hire of Yekaterina Khotskaya as vice president of clinical operations. As head of CureMatch’s clinical operations, Dr. Khotskaya will bring her experience in research, software development, project management, and molecular diagnostics to work hand in hand with clinicians to bring CureMatch’s algorithm to a wider patient base.

Dr. Khotskaya is a former precision oncology scientist and fellow of the MD Anderson’s Institute for Personalized Cancer Therapy, where she was part of a team that built a knowledge base of functional mutation annotations and decision support software to help match cancer patients to appropriate clinical trials—skills that make her a great asset to CureMatch. She has also specialized in software development and commercialization at QIAGEN Bioinformatics and completed a second postdoc from the University of Alabama at Birmingham, where she also earned her PhD in pathology.

“We welcome her to the CureMatch team and look forward to seeing how her unique blend of skills in personalized medicine and software can inform the direction of our clinical operations,” said Bob Manning, CEO.

About CureMatch
CureMatch, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. www.curematch.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/curematch-hires-associate-vice-president-of-clinical-operations-300890491.html

SOURCE CureMatch

Staff

Recent Posts

Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia

LUND, SWEDEN / ACCESSWIRE / March 27, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq…

2 hours ago

RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

Relief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors OverhaulGENEVA, SWITZERLAND / ACCESSWIRE /…

2 hours ago

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Pivotal Trial for Improving Overall Function and Quality of LifeSALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, a pioneer…

11 hours ago

AARC Celebrates Introduction of the SOAR Act in the House of Representatives

Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…

14 hours ago

She Is Not Skipping a Beat, and Patients Are Noticing

NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics At Quest for 2…

14 hours ago